Suchergebnisse - "Antirheumatic Agents"

PubPharm (30.216)

31

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis : a post hoc analysis of a phase 3b/4 randomised safety study

enthalten in: RMD open | 2024

von Buch, M. | Bhatt, D. | Charles-Schoeman, C. | +10

32

Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis

enthalten in: RMD open | 2024

von Song, Y. | Lee, J. | Jo, J. | +1

33

Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts

enthalten in: Annals of the rheumatic diseases | 2024

von Avouac, J. | Hecquet, S. | Thomas, M. | +3

34

Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis

enthalten in: Annals of the rheumatic diseases | 2024

von Crowson, C. | Atkinson, E. | Kronzer, V. | +8

35

Combinational strategy using albumin-based nanoparticles to enable synergetic anti-rheumatic efficacy and reduced hepatotoxicity

enthalten in: International journal of pharmaceutics | 2024

von Li, J. | Zhang, X. | Pan, L. | +4

36

Prognostic modeling in early rheumatoid arthritis : reconsidering the predictive role of disease activity scores

enthalten in: Clinical rheumatology | 2024

von Bird, A. | Oakden-Rayner, L. | Smith, L. | +4

37

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis : real-world data from the BIOBADASER registry

enthalten in: Annals of the rheumatic diseases | 2024

von Hernández-Cruz, B. | Otero-Varela, L. | Freire-González, M. | +11

38

Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis : observational extension of the REDO trial

enthalten in: RMD open | 2024

von den Broeder, N. | Verhoef, L. | de Man, Y. | +7

39

Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption

enthalten in: Lupus science & medicine | 2024

von Parodis, I.

40

OpenSAFELY : The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate

enthalten in: British journal of clinical pharmacology | 2024

von Brown, A. | Fisher, L. | Curtis, H. | +25